{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:18:42Z","timestamp":1778699922822,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40121-025-01180-9","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:35:40Z","timestamp":1755844540000},"page":"2247-2276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis\u00a0C Infection Treated with Direct-Acting Antivirals: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4536-9920","authenticated-orcid":false,"given":"Kristina","family":"Lindsley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candido","family":"Hernandez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marcinak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie E.","family":"Chiuve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Uyei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soodabeh","family":"Navadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna D.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"4","key":"1180_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719\u201326. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.008.","journal-title":"J Hepatol"},{"issue":"11","key":"1180_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.dld.2018.08.001","volume":"50","author":"M Guarino","year":"2018","unstructured":"Guarino M, Vigan\u00f2 L, Ponziani FR, et al. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for Hepatitis\u00a0C virus infection: literature review and risk analysis. Dig Liver Dis. 2018;50(11):1105\u201314. https:\/\/doi.org\/10.1016\/j.dld.2018.08.001.","journal-title":"Dig Liver Dis"},{"key":"1180_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.20517\/2394-5079.2019.15","volume":"5","author":"E Harrod","year":"2019","unstructured":"Harrod E, Moctezuma-Velazquez C, Gurakar A, Ala A, Dieterich D, Saberi B. Management of concomitant hepatocellular carcinoma and chronic Hepatitis\u00a0C: a review. Hepatoma Res. 2019;5:28. https:\/\/doi.org\/10.20517\/2394-5079.2019.15.","journal-title":"Hepatoma Res"},{"key":"1180_CR4","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis\u00a0C: final update of the series. J Hepatol. 2020;73(5):1170\u20131218. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.018.","DOI":"10.1016\/j.jhep.2020.08.018"},{"issue":"6","key":"1180_CR5","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204\u201312. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.025.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"1180_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/liv.13659","volume":"38","author":"B Roche","year":"2018","unstructured":"Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis\u00a0C with DAAs on the occurrence of HCC. Liver Int. 2018;38(Suppl 1):139\u201345. https:\/\/doi.org\/10.1111\/liv.13659.","journal-title":"Liver Int"},{"key":"1180_CR7","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. 2024. www.training.cochrane.org\/handbook. Accessed 26 June 2025."},{"key":"1180_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJMJ Page","year":"2021","unstructured":"Page MJMJ, Bossuyt PM, Boutron I, et al. Mayo-Wilson E, McDonald S, McGuinness LA, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1180_CR9","unstructured":"Direct-acting antivirals (DAAs) for the treatment of chronic hepatitis\u00a0C virus (HCV) infection and the risk of hepatocellular carcinoma (HCC) recurrence: A protocol for a systematic literature review. Published 18 June 2021. https:\/\/catalogues.ema.europa.eu\/node\/2987\/administrative-details. Accessed 26 June 2025."},{"key":"1180_CR10","unstructured":"HTA CG (Member State Coordination Group on Health Technology Assessment). Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. Adopted on 8 March 2024."},{"key":"1180_CR11","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 26 June 2025."},{"issue":"7109","key":"1180_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"1180_CR13","doi-asserted-by":"publisher","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Statist Software 2010;36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","DOI":"10.18637\/jss.v036.i03"},{"key":"1180_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","volume":"15","author":"PT von Hippel","year":"2015","unstructured":"von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15:35. https:\/\/doi.org\/10.1186\/s12874-015-0024-z.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1180_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","volume":"65","author":"ANRS collaborative study group on hepatocellular carcinoma","year":"2016","unstructured":"ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734\u201340.","journal-title":"J Hepatol"},{"issue":"2","key":"1180_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.17998\/jlc.2022.05.24","volume":"22","author":"YH Ahn","year":"2022","unstructured":"Ahn YH, Lee H, Han JE, et al. Effect of direct-acting antivirals for hepatitis\u00a0C virus-related hepatocellular carcinoma recurrence and death after curative treatment. J Liver Cancer. 2022;22(2):125\u201335. https:\/\/doi.org\/10.17998\/jlc.2022.05.24.","journal-title":"J Liver Cancer"},{"issue":"2","key":"1180_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","volume":"71","author":"G Cabibbo","year":"2019","unstructured":"Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71(2):265\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.027.","journal-title":"J Hepatol"},{"key":"1180_CR18","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.14309\/00000434-201710001-00931","volume":"112","author":"Y Chan","year":"2017","unstructured":"Chan Y, Maclennan S, Dixon E, et al. Direct-acting antivirals are not associated with early tumor recurrence after curative treatments in hepatitis\u00a0C-related hepatocellular carcinoma. Am J Gastroenterol. 2017;112:S521\u20133.","journal-title":"Am J Gastroenterol"},{"key":"1180_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020259","author":"YS Chen","year":"2022","unstructured":"Chen YS, Huang KH, Wang PM, et al. The impact of direct-acting antiviral therapy on the risk of recurrence after curative resection in patients with hepatitis-C-virus-related early stage hepatocellular carcinoma. Medicina (Kaunas). 2022. https:\/\/doi.org\/10.3390\/medicina58020259.","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"1180_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jmii.2019.09.006","volume":"54","author":"CT Chi","year":"2019","unstructured":"Chi CT, Chen CY, Su CW, et al. Direct-acting antivirals for patients with chronic hepatitis\u00a0C and hepatocellular carcinoma in Taiwan. J Microbiol Immunol Infect. 2019;54(3):385\u201395. https:\/\/doi.org\/10.1016\/j.jmii.2019.09.006.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"1180_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jvh.12854","volume":"25","author":"M El Kassas","year":"2018","unstructured":"El Kassas M, Funk A, Salaheldin M, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis\u00a0C-infected Egyptian cohort: a comparative analysis. J Viral Hepatitis. 2018;25(6):623\u201330.","journal-title":"J Viral Hepatitis"},{"issue":"10","key":"1180_CR22","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1007\/s10620-017-4739-z","volume":"62","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, Kawamura Y, Kobayashi M, et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis\u00a0C virus-related hepatocellular carcinoma. Dig Dis Sci. 2017;62(10):2932\u201342. https:\/\/doi.org\/10.1007\/s10620-017-4739-z.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"1180_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jvh.13627","volume":"29","author":"H Ikenaga","year":"2022","unstructured":"Ikenaga H, Uchida-Kobayashi S, Tamori A, et al. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat. 2022;29(1):52\u20139. https:\/\/doi.org\/10.1111\/jvh.13627.","journal-title":"J Viral Hepat"},{"issue":"2","key":"1180_CR24","first-page":"111","volume":"12","author":"K Imai","year":"2020","unstructured":"Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis\u00a0C-related hepatocellular carcinoma after curative treatment. Mol Clin Oncol. 2020;12(2):111\u20136.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"1180_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2018.09.029","volume":"70","author":"MN Kinoshita","year":"2019","unstructured":"Kinoshita MN, Minami T, Tateishi R, et al. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy. J Hepatol. 2019;70(1):78\u201386. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.029.","journal-title":"J Hepatol"},{"issue":"1","key":"1180_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s10637-019-00870-9","volume":"38","author":"Y-H Kuo","year":"2020","unstructured":"Kuo Y-H, Wang J-H, Chang K-C, et al. The influence of direct-acting antivirals in hepatitis\u00a0C virus related hepatocellular carcinoma after curative treatment. Invest New Drugs. 2020;38(1):202\u201310.","journal-title":"Invest New Drugs"},{"key":"1180_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092295","author":"R Kuromatsu","year":"2022","unstructured":"Kuromatsu R, Ide T, Okamura S, et al. Hepatitis\u00a0C virus elimination using direct acting antivirals after the radical cure of hepatocellular carcinoma suppresses the recurrence of the cancer. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14092295.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1180_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233212","volume":"15","author":"W-C Lin","year":"2020","unstructured":"Lin W-C, Lin Y-S, Chang C-W, et al. Impact of direct-acting antiviral therapy for hepatitis\u00a0C\u2013related hepatocellular carcinoma. PLoS One. 2020;15(5):e0233212.","journal-title":"PLoS One"},{"issue":"4","key":"1180_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194704","volume":"13","author":"T Mashiba","year":"2018","unstructured":"Mashiba T, Joko K, Kurosaki M, et al. Does interferon-free direct-acting antiviral therapy for hepatitis\u00a0C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS One. 2018;13(4):e0194704. https:\/\/doi.org\/10.1371\/journal.pone.0194704.","journal-title":"PLoS One"},{"issue":"7","key":"1180_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/jvh.13684","volume":"29","author":"T Mashiba","year":"2022","unstructured":"Mashiba T, Joko K, Kurosaki M, et al. Efficacy of hepatitis\u00a0C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: a nationwide, multicentre study by the Japanese Red Cross Liver Study Group. J Viral Hepat. 2022;29(7):551\u20138. https:\/\/doi.org\/10.1111\/jvh.13684.","journal-title":"J Viral Hepat"},{"key":"1180_CR31","doi-asserted-by":"publisher","unstructured":"Minami T, Tateishi R, Nakagomi R, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis\u00a0C-related hepatocellular carcinoma. J Hepatol 2016;65(6):1272\u20131273. Comment on: J Hepatol. 2016;65(4):719\u2013726. [https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27084592]. https:\/\/doi.org\/10.1016\/j.jhep.2016.07.043.","DOI":"10.1016\/j.jhep.2016.07.043"},{"issue":"7","key":"1180_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2169\/internalmedicine.3382-19","volume":"59","author":"S Miuma","year":"2020","unstructured":"Miuma S, Miyamoto J, Taura N, et al. Influence of interferon-free direct-acting antiviral therapy on primary hepatocellular carcinoma recurrence: a landmark time analysis and time-dependent extended cox proportional hazards model analysis. Intern Med. 2020;59(7):901\u20137.","journal-title":"Intern Med"},{"issue":"18","key":"1180_CR33","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.2169\/internalmedicine.8456-21","volume":"61","author":"Y Mori","year":"2022","unstructured":"Mori Y, Matsuda S, Sato M, et al. The impact of antiviral therapy for hepatitis\u00a0C virus on the survival of patients after hepatocellular carcinoma treatment. Intern Med. 2022;61(18):2721\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.8456-21.","journal-title":"Intern Med"},{"key":"1180_CR34","doi-asserted-by":"crossref","unstructured":"Muzica C-M, Trifan A, Huiban L, et al. Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals. Int Liver Congress EASL 2022 London.","DOI":"10.1016\/S0168-8278(22)01470-2"},{"issue":"4","key":"1180_CR35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jmv.25352","volume":"91","author":"Y Nagaoki","year":"2019","unstructured":"Nagaoki Y, Imamura M, Nishida Y, et al. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis\u00a0C virus\u2013associated hepatocellular carcinoma: comparison with interferon-based therapy. J Med Virol. 2019;91(4):650\u20138.","journal-title":"J Med Virol"},{"issue":"5","key":"1180_CR36","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","volume":"67","author":"H Nagata","year":"2017","unstructured":"Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis\u00a0C. J Hepatol. 2017;67(5):933\u20139.","journal-title":"J Hepatol"},{"issue":"1","key":"1180_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00535-020-01747-y","volume":"56","author":"H Ochi","year":"2021","unstructured":"Ochi H, Hiraoka A, Hirooka M, et al. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol. 2021;56(1):90\u2013100. https:\/\/doi.org\/10.1007\/s00535-020-01747-y.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1180_CR38","first-page":"207A","volume":"70","author":"T Ohki","year":"2019","unstructured":"Ohki T, Sato K, Kondo M, et al. Eradication of hepatitis\u00a0C virus using direct acting antiviral agents leads to an alteration of liver function and a reduction of hepatocellular carcinoma recurrence rates even in patients with multiple courses of recurrence. Hepatology. 2019;70(1):207A-208A.","journal-title":"Hepatology"},{"issue":"11","key":"1180_CR39","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jvh.13579","volume":"28","author":"T Ohki","year":"2021","unstructured":"Ohki T, Sato K, Kondo M, et al. Effectiveness of direct acting antiviral agents for hepatitis\u00a0C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence. J Viral Hepat. 2021;28(11):1597\u2013603. https:\/\/doi.org\/10.1111\/jvh.13579.","journal-title":"J Viral Hepat"},{"key":"1180_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)31231-9","volume":"70","author":"C Perello","year":"2019","unstructured":"Perello C, Llop E, Calleja P, et al. Recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice. J Hepatol. 2019;70:e617.","journal-title":"J Hepatol"},{"issue":"5","key":"1180_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/2050640619841254","volume":"7","author":"CM Preda","year":"2019","unstructured":"Preda CM, Baicus C, Sandra I, et al. Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis\u00a0C virus-associated cirrhosis after ombitasvir\/paritaprevir\/ritonavir+dasabuvir+ribavirin therapy. United Eur Gastroenterol J. 2019;7(5):699\u2013708. https:\/\/doi.org\/10.1177\/2050640619841254.","journal-title":"United Eur Gastroenterol J"},{"issue":"Suppl 1","key":"1180_CR42","doi-asserted-by":"publisher","first-page":"S1189","DOI":"10.1016\/S0168-8278(23)03341-X","volume":"78","author":"A Singal","year":"2023","unstructured":"Singal A, Fried M, Colombo M, et al. A prospective, pragmatic post-authorisation safety study of early recurrence of hepatocellular carcinoma in hepatitis\u00a0C virus-infected patients after direct-acting antiviral (DAA) therapy: DAA-PASS. J Hepatol. 2023;78(Suppl 1):S1189.","journal-title":"J Hepatol"},{"issue":"10","key":"1180_CR43","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/hepr.13547","volume":"50","author":"Y Tahata","year":"2020","unstructured":"Tahata Y, Sakamori R, Urabe A, et al. Clinical outcomes of direct-acting antiviral treatments for patients with Hepatitis\u00a0C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatol Res. 2020;50(10):1118\u201327. https:\/\/doi.org\/10.1111\/hepr.13547.","journal-title":"Hepatol Res"},{"issue":"8","key":"1180_CR44","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/jso.26184","volume":"122","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Shinkawa H, Tamori A, et al. Surgical outcomes for hepatocellular carcinoma detected after hepatitis\u00a0C virus eradiation by direct-acting antivirals. J Surg Oncol. 2020;122(8):1543\u201352.","journal-title":"J Surg Oncol"},{"issue":"11","key":"1180_CR45","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/hepr.13709","volume":"51","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Shinkawa H, Tamori A, et al. Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis\u00a0C virus-related hepatocellular carcinoma. Hepatol Res. 2021;51(11):1102\u201314. https:\/\/doi.org\/10.1111\/hepr.13709.","journal-title":"Hepatol Res"},{"issue":"66","key":"1180_CR46","doi-asserted-by":"publisher","first-page":"S533","DOI":"10.1016\/S0168-8278(17)31469-1","volume":"1","author":"L Telep","year":"2017","unstructured":"Telep L, Muramoto D, Osinusi A, et al. No increased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis\u00a0C virus: a cohort study using large-scale administrative medical claims data. J Hepatol. 2017;1(66):S533.","journal-title":"J Hepatol"},{"issue":"1","key":"1180_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/cancers12010023","volume":"12","author":"W Teng","year":"2020","unstructured":"Teng W, Jeng W-J, Yang H-I, et al. Interferon is superior to direct acting antiviral therapy in tertiary prevention of early recurrence of hepatocellular carcinoma. Cancers. 2020;12(1):23.","journal-title":"Cancers"},{"issue":"8","key":"1180_CR48","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/liv.13456","volume":"37","author":"V Virlogeux","year":"2017","unstructured":"Virlogeux V, Pradat P, Hartig-Lavie K, et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis\u00a0C. Liver Int. 2017;37(8):1122\u20137.","journal-title":"Liver Int"},{"issue":"1","key":"1180_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jvh.12651","volume":"24","author":"R Vukotic","year":"2017","unstructured":"Vukotic R, Di Donato R, Conti F, Scuteri A, Serra C, Andreone P. Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort. J Viral Hepatitis. 2017;24(1):13\u20136.","journal-title":"J Viral Hepatitis"},{"key":"1180_CR50","first-page":"147","volume":"4","author":"K Warzyszynska","year":"2018","unstructured":"Warzyszynska K, Jonas M, Wasiak D, Malkowski P. Decreased hepatocellular carcinoma (HCC) recurrence rate after postoperative direct-acting antivirals treatment. Clin Experim Hepatol. 2018;4:147.","journal-title":"Clin Experim Hepatol"},{"key":"1180_CR51","unstructured":"Woo HY, Heo J, Park YJ. Real-world effectiveness and safety of antiviral therapy in patients with hepatitis C-related hepatocellular carcinoma. Hoboken: Wiley."},{"issue":"66","key":"1180_CR52","doi-asserted-by":"publisher","first-page":"S748","DOI":"10.1016\/S0168-8278(17)31990-6","volume":"1","author":"Y Yasui","year":"2017","unstructured":"Yasui Y, Kurosaki M, Wang W, et al. Direct acting antivirals did not increase early recurrences after curative treatment of HCV related hepatocellular carcinoma in comparison with IFN-based treatment. J Hepatol. 2017;1(66):S748.","journal-title":"J Hepatol"},{"key":"1180_CR53","first-page":"759A","volume":"66","author":"H Yoshida","year":"2017","unstructured":"Yoshida H, Goto E, Koike Y, et al. Direct acting antiviral therapy after curative treatment of hepatocellular carcinoma improved recurrence free survival rate. Hepatology. 2017;66:759A.","journal-title":"Hepatology"},{"key":"1180_CR54","unstructured":"Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated February 2022). Cochrane. 2024. www.training.cochrane.org\/handbook. Accessed 26 June 2025."},{"issue":"3","key":"1180_CR55","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s40471-018-0155-y","volume":"5","author":"M D\u2019Arcy","year":"2018","unstructured":"D\u2019Arcy M, Sturmer T, Lund JL. The importance and implications of comparator selection in pharmacoepidemiologic research. Curr Epidemiol Rep. 2018;5(3):272\u201383. https:\/\/doi.org\/10.1007\/s40471-018-0155-y.","journal-title":"Curr Epidemiol Rep"},{"issue":"3","key":"1180_CR56","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","volume":"71","author":"V Sapena","year":"2022","unstructured":"Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut. 2022;71(3):593\u2013604. https:\/\/doi.org\/10.1136\/gutjnl-2020-323663.","journal-title":"Gut"},{"key":"1180_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081694","author":"L Frazzoni","year":"2021","unstructured":"Frazzoni L, Sikandar U, Metelli F, et al. Hepatocellular carcinoma recurrence after hepatitis C virus therapy with direct-acting antivirals. A systematic review and meta-analysis. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10081694.","journal-title":"J Clin Med"},{"key":"1180_CR58","doi-asserted-by":"crossref","unstructured":"Nakagawa M, Asahina Y, Tsuchiya J, et al. SAT-253-Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients. J Hepatol. 2019;70(1):e744\u20135.","DOI":"10.1016\/S0618-8278(19)31486-0"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01180-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:27:08Z","timestamp":1759138028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01180-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01180-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kristina Lindsley, Yi Wang, and Jenny Uyei are employees of IQVIA, which received funding from AbbVie, Inc., Gilead Sciences, Inc., and Merck & Co., Inc. to conduct this study. Margaret Burroughs was an employee of AbbVie, Inc. when this study was conducted. John Marcinak and Stephanie E Chiuve are employees of and hold stock with AbbVie, Inc. Candido Hernandez-Lopez, Soodabeh Navadeh, and Giuseppe De Marco are employees of Gilead Sciences, Inc. Barbara A Haber and Deanna D Hill are employees and shareholders of Merck & Co., Inc. They conducted the study as part of their employment using company resources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}